Prof. Dr. Jef Rozenski

contact

• see whoiswho
• Erasmus(+) students welcome, send me an email.

research projects

• An NMR facility tailored for biomedical research [more...]
• Streamlining the route of phosphonate XNA from chemistry to application [more...]
• Directed evolution of bioactive compounds: Azol(in)e-containing post-translationally modified peptides [more...]
• Development of XNA ligases as tools for synthetic biology [more...]

recent publications

• Bulai, R-G., Van Eynde, W., Heylen, S., Cremonini, M., Van Olmen, F., Wicik, R., Lescrinier, E., Rozenski, J., Voet, A., Masschelein, J., Verwilst, P. with Masschelein, J. (corresp. author), Verwilst, P. (corresp. author) (2025). Investigating the structure-activity-relationship of diaryl ether-based paFabV inhibitors: A path to novel antibacterials. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 296, Art.No. ARTN 117782. doi: 10.1016/j.ejmech.2025.117782
• Goffin, E., Torfs, L., Tsingis, F., Svestka, D., Erven, K., Uyttersprot, K., Heens, C., Wilms, S., Rozenski, J., Lescrinier, E., Pannecouque, C., Verwilst, P. with Verwilst, P. (corresp. author) (2025). Discovery and SAR exploration of novel nanomolar 3,4-dihydroquinazolin-2(1H)-one non-nucleoside reverse transcriptase inhibitors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 296, Art.No. ARTN 117818. doi: 10.1016/j.ejmech.2025.117818
• Billen, M., Reynders, S., Claes, S., Kleinboelting, S., Rozenski, J., Bulai, R-G., Rocca, E., Homer, N.Z M., Webster, S.P., Kaminski, T.P., Lescrinier, E., Schols, D., Verwilst, P. with Verwilst, P. (corresp. author) (2025). Discovery and exploration of disubstituted [1,2,5]oxadiazolo-[3,4-b]pyrazines as novel C-C chemokine receptor type 5 signaling inhibitors targeting the intracellular allosteric binding pocket. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 291, Art.No. ARTN 117600. doi: 10.1016/j.ejmech.2025.117600
• Goffin, E., Torfs, L., Švestka, D., Erven, K., Uyttersprot, K., Heens, C., Wilms, S., Rozenski, J., Lescrinier, E., Pannecouque, C., Verwilst, P. with Verwilst, P. (corresp. author) (2025). Discovery and SAR Exploration of Novel Nanomolar 3,4-dihydroquinazolin-2(1H)-one Non-Nucleoside Reverse Transcriptase Inhibitors. ChemRxiv. doi: 10.26434/chemrxiv-2025-8l8jw
• Van Loy, B., Pujol, E., Kamata, K., Lee, X.Y., Bakirtzoglou, N., Van Berwaer, R., Vandeput, J., Mestdagh, C., Persoons, L., De Wijngaert, B., Goovaerts, Q., Noppen, S., Jacquemyn, M., Ahmadzadeh, K., Bernaerts, E., Martin-Lopez, J., Escriche, C., Vanmechelen, B., Krasniqi, B., Singh, A.K., Daelemans, D., Maes, P., Matthys, P., Dehaen, W., Rozenski, J., Das, K., Voet, A., Vazquez, S., Naesens, L., Stevaert, A. with Naesens, L. (corresp. author) (2025). A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses. PLOS PATHOGENS, 21 (2), Art.No. ARTN e1012571. doi: 10.1371/journal.ppat.1012571
• Billen, M., Reynders, S., Claes, S., Kleinboelting, S., Rozenski, J., Bulai, R., Rocca, E., Homer, N.Z M., Webster, S.P., Kaminski, T.P., Lescrinier, E., Schols, D., Verwilst, P. (2024). Discovery and Exploration of Disubstituted [1,2,5]Oxadiazolo-[3,4-B]Pyrazines as Novel C-C Chemokine Receptor Type 5 Signaling Inhibitors Targeting the Intracellular Allosteric Binding Pocket. SSRN.
• Bulai, R-G., Heylen, S., Cremonini, M., Lescrinier, E., Rozenski, J., Masschelein, J., Verwilst, P. (2024). Development of Diaryl Ether-based FabV Inhibitors Aimed Against P. aeruginosa. Presented at the EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC), Rome, Italy, 01 Sep 2024-05 Sep 2024.
• Bulai, R-G., Heylen, S., Cremonini, M., Lescrinier, E., Rozenski, J., Masschelein, J., Verwilst, P. with Masschelein, J. (corresp. author), Verwilst, P. (corresp. author) (2023). Exploring the Structure-Activity-Relationship of the ‘B’-ring in Diaryl Ether-Based paFabV Inhibitors. ChemRxiv. doi: 10.26434/chemrxiv-2023-5rgkp
• Van De Sijpe, G., Mylemans, M., Alvarez, L.A., Ozbey, A.C., Allegaert, K., Rozenski, J., Annaert, P., Desmet, S., Spriet, I. with Van De Sijpe, G. (corresp. author) (2023). Assessment of in vitro antimicrobial activity of clindamycin metabolites against Staphylococcus species. Clinical Microbiology And Infection, 29 (10), 1345-1347. doi: 10.1016/j.cmi.2023.07.005
• Martina, M.G., Giammarino, F., Vicenti, I., Groaz, E., Rozenski, J., Incerti, M., Sannio, F., Docquier, J.D., Zazzi, M., Radi, M. with Radi, M. (corresp. author) (2023). Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties. CHEMMEDCHEM, 18 (16). doi: 10.1002/cmdc.202300200

For a complete list of publications, see lirias database or PubMed.

links

• Our expertise is available at the Bioanalytical Mass Spectrometry Facility where we offer mass spectrometry services. See website for details.
• the Mass Spectrometry Toolbox
• Belgian Society for Mass Spectrometry
• RNA Modification Database
• SSU Modification Database